Atovaquoneinteractions
atovaquone 250 MG / proguanil hydrochloride 100 MG Oral Tablet
This is the interactions section of this product’s FDA label — what the manufacturer documented for this drug. It is not a check of your medication list, and a drug missing from it has not been cleared: licensed clinical databases list far more interactions than any single label does. Before combining medicines, ask a pharmacist, who can check everything you take at once and will do it for free.
Named on this label
Every name above is printed in the text below. This is not the full set of drugs that interact with this one — it is the set this manufacturer wrote down.
Drug interactions
Administration with rifampin or rifabutin is known to reduce atovaquone concentrations; concomitant use with atovaquone and proguanil hydrochloride tablets is not recommended. Proguanil may potentiate anticoagulant effect of warfarin and other coumarin-based anticoagulants. Caution advised when initiating or withdrawing atovaquone and proguanil hydrochloride tablets in patients on anticoagulants; coagulation tests should be closely monitored. Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored.
7.1 Rifampin/Rifabutin
Concomitant administration of rifampin or rifabutin is known to reduce atovaquone concentrations. The concomitant administration of atovaquone and proguanil hydrochloride tablets and rifampin or rifabutin is not recommended.
7.2 Anticoagulants
Proguanil may potentiate the anticoagulant effect of warfarin and other coumarin-based anticoagulants. The mechanism of this potential drug interaction has not been established. Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with atovaquone and proguanil hydrochloride tablets in patients on continuous treatment with coumarin-based anticoagulants. When these products are administered concomitantly, coagulation tests should be closely monitored.
7.3 Tetracycline
Concomitant treatment with tetracycline has been associated with a reduction in plasma concentrations of atovaquone. Parasitemia should be closely monitored in patients receiving tetracycline.
7.4 Metoclopramide
While antiemetics may be indicated for patients receiving atovaquone and proguanil hydrochloride tablets, metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available.
7.5 Indinavir
Concomitant administration of atovaquone and indinavir did not result in any change in the steady-state AUC and C max of indinavir but resulted in a decrease in the C trough of indinavir. Caution should be exercised when prescribing atovaquone with indinavir due to the decrease in trough concentrations of indinavir.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective December 11, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance